Tag Archives: Saatchi Bill

Editors’ introduction: The Medical Innovation Bill proposed by Lord Maurice Saatchi, which would have allowed doctors to treat terminally ill patients with new and experimental treatments instead of having to stick to standard procedures, has given rise to heated debate across the medical community. Recently vetoed by the Liberal Democrats, who now promise a full examination of the issue, it is even more important for healthcare professionals to voice their opinions. We present one view below on the Bill’s ambitions and implications, which we hope will stimulate debate. Have your say now in the comments section at the end of the artic

NICE NOAC guidance The National Institute for Health and Care Excellence (NICE) has recently published two recommendations on the use of novel oral anticoagulants (NOACs). NICE has recommended the NOAC dabigatran as an option for treating and preventing deep-vein thrombosis (DVT) and pulmonary embolism (PE) in adults (available in full at http://www.nice.org.uk/guidance/ta327) A final appraisal determination has also been issued for the NOAC rivaroxaban. It recommends it is an effective treatment option for preventing secondary events after acute coronary syndrome in patients with elevated cardiac biomarkers. Publication of full guidance is e